These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1335668)

  • 41. Cost-effectiveness analysis of hepatitis A vaccination strategies for adults.
    O'Connor JB; Imperiale TF; Singer ME
    Hepatology; 1999 Oct; 30(4):1077-81. PubMed ID: 10498662
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of postexposure vaccination in a chimpanzee model of hepatitis A virus infection.
    Robertson BH; D'Hondt EH; Spelbring J; Tian H; Krawczynski K; Margolis HS
    J Med Virol; 1994 Jul; 43(3):249-51. PubMed ID: 7931186
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatitis A and hepatitis B: risks compared with other vaccine preventable diseases and immunization recommendations.
    Steffen R
    Vaccine; 1993; 11(5):518-20. PubMed ID: 8387717
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatitis A vaccines and the elderly.
    Genton B; D'Acremont V; Furrer HJ; Hatz C; Louis Loutan
    Travel Med Infect Dis; 2006 Dec; 4(6):303-12. PubMed ID: 17098625
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of hepatitis A vaccination for adults in Belgium.
    Luyten J; Van de Sande S; de Schrijver K; Van Damme P; Beutels P
    Vaccine; 2012 Sep; 30(42):6070-80. PubMed ID: 22858555
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies.
    Anonychuk AM; Tricco AC; Bauch CT; Pham B; Gilca V; Duval B; John-Baptiste A; Woo G; Krahn M
    Pharmacoeconomics; 2008; 26(1):17-32. PubMed ID: 18088156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-benefit analysis of hepatitis a vaccination in Thailand.
    Teppakdee A; Tangwitoon A; Khemasuwan D; Tangdhanakanond K; Suramaethakul N; Sriratanaban J; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2002 Mar; 33(1):118-27. PubMed ID: 12118439
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The value of immunization against hepatitis A.
    Lemon SM; Shapiro CN
    Infect Agents Dis; 1994 Feb; 3(1):38-49. PubMed ID: 7952926
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vaccination against hepatitis A for travellers. Will alter the dynamics of transmission in Britain.
    Neal K
    BMJ; 1995 Jan; 310(6971):61. PubMed ID: 7827576
    [No Abstract]   [Full Text] [Related]  

  • 50. Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin.
    Green MS; Cohen D; Lerman Y; Sjogren M; Binn LN; Zur S; Slepon R; Robin G; Hoke C; Bancroft W
    J Infect Dis; 1993 Sep; 168(3):740-3. PubMed ID: 8394864
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Passive immunization against hepatitis A.
    Stapleton JT
    Vaccine; 1992; 10 Suppl 1():S45-7. PubMed ID: 1335658
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis A: epidemiology in resource-poor countries.
    Aggarwal R; Goel A
    Curr Opin Infect Dis; 2015 Oct; 28(5):488-96. PubMed ID: 26203853
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anti-HAV seroprevalence in German travellers and hepatitis A vaccination in immune subjects.
    Bienzle U; Bock HL; Meister W; Clemens R; Kruppenbacher JP
    Lancet; 1993 Apr; 341(8851):1028. PubMed ID: 8096914
    [No Abstract]   [Full Text] [Related]  

  • 54. Cost-utility analysis of hepatitis A prevention among health-care workers in Israel.
    Chodick G; Lerman Y; Wood F; Aloni H; Peled T; Ashkenazi S
    J Occup Environ Med; 2002 Feb; 44(2):109-15. PubMed ID: 11851212
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Studies on immunization strategy against hepatitis A in a highly prevalent area].
    Zhang Y; Ma J; Zhao S
    Zhonghua Yu Fang Yi Xue Za Zhi; 1998 Sep; 32(5):295-6. PubMed ID: 10322776
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High prevalence of hepatitis A virus antibody among Bangladeshi children and young adults warrants pre-immunization screening of antibody in HAV vaccination strategy.
    Ahmed M; Munshi SU; Nessa A; Ullah MS; Tabassum S; Islam MN
    Indian J Med Microbiol; 2009; 27(1):48-50. PubMed ID: 19172060
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Active versus passive immunization against hepatitis A in the Israel defence forces: a cost-benefit analysis.
    Gillis D; Yetiv N; Gdalevich M; Mimouni D; Ashkenazi I; Shpilberg O; Eldad A; Shemer J
    Vaccine; 2000 Jul; 18(26):3005-10. PubMed ID: 10825603
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New hepatitis A vaccines and their role in prevention.
    Strader DB; Seeff LB
    Drugs; 1996 Mar; 51(3):359-66. PubMed ID: 8882375
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness of hepatitis A vaccination in Indonesia.
    Suwantika AA; Beutels P; Postma MJ
    Hum Vaccin Immunother; 2014; 10(8):2342-9. PubMed ID: 25424941
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cost-benefit analysis for hepatitis A vaccine].
    Chen E; Yao J; Yang J
    Zhonghua Liu Xing Bing Xue Za Zhi; 1999 Aug; 20(4):224-7. PubMed ID: 10682501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.